David B. Agus, MD

Professor of Medicine and Biomedical Engineering

Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

Director, USC Center for Applied Molecular Medicine

Image of David B. Agus, MD
Is this your profile? Click to edit

Overview

David B. Agus is a professor of medicine and engineering at the University of Southern California’s Keck School of Medicine and Viterbi School of Engineering. He is the founding director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. A medical oncologist, Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs. An international leader in new technologies and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and the Global Health Security Consortium. He is also a CBS News contributor. Dr. Agus’ three books “The End of Illness”, “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are all New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital and fellowship at Memorial Sloan-Kettering Cancer Center.

Awards

  • American Cancer Society: Physician Research Award, 1996
     – 2001
  • Sloan-Kettering Institute: Clinical Scholar Award, 1996
  • American Cancer Society: Clinical Oncology Fellowship Award, 1994
  • HealthNetwork Foundation: Excellence Award, 2008
  • Geoffrey Beene Foundation: Rock Stars of Science™, 2009
  • Biotech Humanitarian Award: Selected Judge, 2009
  • USC Association of Trojan Leagues: Outstanding Service Award, 2013
  • American College of Physicians: Fellow, 2016
  • Ellis Island Medal of Honor: Medalist, 2017

Research Funding

  • (PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
    NIH · R01CA180149 · Sep 5, 2013 – Jul 31, 2018 · Role: Principal Investigator
  • UCLA SPORE in Prostate Cancer
    NIH · P50CA092131 · Jul 1, 2001 – Aug 31, 2024 · Role: Co-Principal Investigator

Publications

  • Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000 Sep 15; 60(18):5165-70.. View in PubMed
  • Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 2000 May 01; 60(9):2317-22.. View in PubMed
  • Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999 Dec; 17(12):3776-85.. View in PubMed
  • Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999 Nov 03; 91(21):1869-76.. View in PubMed
  • Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 1999 Oct 01; 59(19):4761-4.. View in PubMed
  • Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res. 1999 Sep 15; 59(18):4555-8.. View in PubMed
  • Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res. 1998 Jul 15; 58(14):3009-14.. View in PubMed
  • Workgroup 2: human xenograft models of prostate cancer. Prostate. 1998 Jun 15; 36(1):56-8.. View in PubMed
  • Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1997 Dec 01; 100(11):2842-8.. View in PubMed